Imperial College London
Portrait Picture

ProfessorPaulFreemont

Faculty of Medicine, Department of Infectious Disease

Chair in Protein Crystallography
 
 
 
//

Contact

 

+44 (0)20 7594 5327p.freemont

 
 
//

Location

 

259Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lund-Palau:2016:10.1080/17476348.2016.1177460,
author = {Lund-Palau, H and Turnbull, AR and Bush, A and Bardin, E and Cameron, L and Soren, O and Wierre-Gore, N and Alton, EW and Bundy, JG and Connett, G and Faust, SN and Filloux, A and Freemont, P and Jones, A and Khoo, V and Morales, S and Murphy, R and Pabary, R and Simbo, A and Schelenz, S and Takats, Z and Webb, J and Williams, HD and Davies, JC},
doi = {10.1080/17476348.2016.1177460},
journal = {Expert Review of Respiratory Medicine},
pages = {685--697},
title = {Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches},
url = {http://dx.doi.org/10.1080/17476348.2016.1177460},
volume = {10},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa occurs early, and although eradication can be achieved following early detection, chronic infection occurs in over 60% of adults with CF. Chronic infection is associated with accelerated disease progression and increased mortality. Extensive research has revealed complex mechanisms by which P. aeruginosa adapts to and persists within the CF airway. Yet knowledge gaps remain, and prevention and treatment strategies are limited by the lack of sensitive detection methods and by a narrow armoury of antibiotics. Further developments in this field are urgently needed in order to improve morbidity and mortality in people with CF. Here, we summarize current knowledge of pathophysiological mechanisms underlying P. aeruginosa infection in CF. Established treatments are discussed, and an overview is offered of novel detection methods and therapeutic strategies in development.
AU  - Lund-Palau,H
AU  - Turnbull,AR
AU  - Bush,A
AU  - Bardin,E
AU  - Cameron,L
AU  - Soren,O
AU  - Wierre-Gore,N
AU  - Alton,EW
AU  - Bundy,JG
AU  - Connett,G
AU  - Faust,SN
AU  - Filloux,A
AU  - Freemont,P
AU  - Jones,A
AU  - Khoo,V
AU  - Morales,S
AU  - Murphy,R
AU  - Pabary,R
AU  - Simbo,A
AU  - Schelenz,S
AU  - Takats,Z
AU  - Webb,J
AU  - Williams,HD
AU  - Davies,JC
DO  - 10.1080/17476348.2016.1177460
EP  - 697
PY  - 2016///
SN  - 1747-6348
SP  - 685
TI  - Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
T2  - Expert Review of Respiratory Medicine
UR  - http://dx.doi.org/10.1080/17476348.2016.1177460
UR  - http://hdl.handle.net/10044/1/38770
VL  - 10
ER  -
Download